| Title |
A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation
|
|---|---|
| Published in |
Acta Neuropathologica, August 2015
|
| DOI | 10.1007/s00401-015-1467-3 |
| Pubmed ID | |
| Authors |
Cheng-Ying Ho, Bret C. Mobley, Heather Gordish-Dressman, Christopher J. VandenBussche, Gary E. Mason, Miriam Bornhorst, Adam J. Esbenshade, Mahtab Tehrani, Brent A. Orr, Delecia R. LaFrance, Joseph M. Devaney, Beatrix W. Meltzer, Sean E. Hofherr, Peter C. Burger, Roger J. Packer, Fausto J. Rodriguez |
| Abstract |
Among brain tumors, the BRAF (V600E) mutation is frequently associated with pleomorphic xanthoastrocytomas (PXAs) and gangliogliomas (GGs). This oncogenic mutation is also detected in ~5 % of other pediatric low-grade gliomas (LGGs) including pilocytic astrocytomas (PAs) and diffuse astrocytomas. In the current multi-institutional study of 56 non-PXA/non-GG diencephalic pediatric LGGs, the BRAF (V600) mutation rate is 36 %. V600-mutant tumors demonstrate a predilection for infants and young children (<age 3) and have a higher tendency for multicentricity. On neuroimaging, BRAF (V600)-mutant tumors appear as nodular, yet infiltrative contrast-enhancing masses. Morphologic examination reveals a monophasic, predominantly compact and partially infiltrative architecture. Due to the lack of classic morphologic features associated with PAs, pilomyxoid astrocytomas (PMAs), or diffuse astrocytomas, 75 % of the BRAF (V600)-mutant tumors could not be definitively classified on initial histopathologic evaluation. At a median follow-up of 55 months, the 5-year progression-free survival (PFS) rate for BRAF (V600)-mutant diencephalic low-grade astrocytomas (LGAs) was 22 ± 12 %, shorter than BRAF (V600)-WT PAs (52 ± 13 %) but higher than PMAs (10 ± 6 %). Of note, long-term PFS was observed in several adolescent patients with BRAF (V600)-mutant tumors. In children aged 0-12 years, 5-year PFS rate and median PFS in BRAF (V600)-mutant LGAs are 9 ± 9 % and 19 months (95 % CI 3-37 months), respectively. The PFS is comparable to that in BRAF (V600)-WT PMAs (5-year PFS rate: 10 ± 9 %; median PFS: 15 months, 95 % CI 3-32 months; p = 0.96) and significantly shorter than BRAF (V600)-WT PAs (5-year PFS rate: 46 ± 13 %; median PFS: 51 months, 95 % CI 20-∞ months; p < 0.05). In summary, diencephalic BRAF (V600)-mutant pediatric LGAs are associated with unique clinicopathologic features and have a more aggressive clinical course, especially in children under age 13. The low rate of CDKN2A deletion also suggests that these tumors are molecularly distinct from secondary pediatric high-grade gliomas. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 59 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Japan | 2 | 3% |
| Spain | 1 | 2% |
| Czechia | 1 | 2% |
| France | 1 | 2% |
| Unknown | 54 | 92% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 24% |
| Other | 7 | 12% |
| Student > Doctoral Student | 5 | 8% |
| Student > Postgraduate | 5 | 8% |
| Student > Master | 4 | 7% |
| Other | 13 | 22% |
| Unknown | 11 | 19% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 30 | 51% |
| Neuroscience | 4 | 7% |
| Biochemistry, Genetics and Molecular Biology | 3 | 5% |
| Psychology | 3 | 5% |
| Sports and Recreations | 1 | 2% |
| Other | 2 | 3% |
| Unknown | 16 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 18 May 2018.
All research outputs
#15,342,608
of 22,821,814 outputs
Outputs from Acta Neuropathologica
#2,099
of 2,369 outputs
Outputs of similar age
#155,012
of 264,494 outputs
Outputs of similar age from Acta Neuropathologica
#15
of 18 outputs
Altmetric has tracked 22,821,814 research outputs across all sources so far. This one is in the 22nd percentile – i.e., 22% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,369 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 14.3. This one is in the 8th percentile – i.e., 8% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 264,494 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 32nd percentile – i.e., 32% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 18 others from the same source and published within six weeks on either side of this one. This one is in the 16th percentile – i.e., 16% of its contemporaries scored the same or lower than it.